搜索结果

Search Results for " ret in 3 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T9673	RET-IN-3	c-RET	Apoptosis; Tyrosine Kinase/Adaptors
	RET-IN-3 是一种具有选择性和高效性的 RETV804M 激酶抑制剂，具有潜在抗癌活性,可用于研究非小细胞肺癌。
T79726	RET-IN-25
	RET-IN-25（化合物6b）是一种具有抗癌活性的RET激酶抑制剂。该化合物能够抑制甲状腺髓样癌（MTC），在TT(C634R) MTC细胞系中的IC50值分别为3.6 μM（3天）和3.0 μM（6天）。
T1656L	Vandetanib Fumarate HSDB 8198,Zactima,Caprelsa,ZD 6474,Vandetanib
	Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a
T78871	PLM-101
	PLM-101是一种口服抗癌剂，针对FLT3和RET具有选择性抑制作用，有效抑制急性髓系白血病（AML）细胞。通过抑制RET，PLM-101促使FLT3的自噬降解，并且通过抑制PI3K和Ras/ERK信号通路来发挥其抗白血病的活性。在小鼠MV4-11侧翼异种移植模型中，PLM-101以口服剂量3及10 mg/kg显示出抗肿瘤效果，并且在同种异种移植小鼠模型中，剂量为40 mg/kg（口服）亦展现出明显的抗肿瘤功效。
T38653	HG-7-85-01
	HG-7-85-01 is a type II ATP competitive inhibitor targeting wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. It effectively inhibits T315I mutant Bcr-Abl kinase, as well as KDR and RET kinases with IC50 values of 3 nM, 20 nM, and 30 nM, respectively. In contrast, HG-7-85-01 exhibits weak or no inhibition towards other kinases (IC50 >2 μM). Furthermore, this compound inhibits cell proliferation through the induction of apoptosis and by impeding cell-cycle progres...
T37582	Ganglioside GM1 Mixture (ovine) (ammonium salt)
	Ganglioside GM1is a monosialylated ganglioside and the prototypic ganglioside for those containing one sialic acid residue.1,2It is found in a large variety of cells, including immune cells and neurons, and is enriched in lipid rafts in the cell membrane.3It associates with growth factor receptors, including TrkA, TrkB, and the GDNF receptor complex containing Ret and GFRα, and is required for TrkA expression on the cell surface. Ganglioside GM1interacts with other proteins to increase calcium i...